CancerIQ, a Chicago, Illinois-based platform powering early cancer detection and prevention across broad patient populations, announced that it closed a $14 million Series B financing.
The round was co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures. McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), as well as CancerIQ’s Series A lead investor, HealthX Ventures, also participated in the Series B round.
The new funding will help CancerIQ grow its precision health platform, strengthen its partnership ecosystem, and expand its health system network. Following a recent series of key executive hires, the company also plans to hire 50 team members to meet the rising demand for more efficient and innovative cancer prevention services.
Company: CancerIQ, Inc.
Round: Series B
Funding Month: March 2022
Lead Investors: Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures
Additional Investors: McKesson Ventures, OSF Ventures, and HealthX Ventures
Company Website: https://www.canceriq.com/
Software Category: precision health platform
About the Company: CancerIQ, Inc. is a cloud-based software that makes it easier for providers to offer the genetic cancer risk assessment to patients. CancerIQ is the only cancer-focused precision health platform that empowers healthcare providers to detect cancer earlier and prevent it altogether across all patient populations. Integrated directly into real-time EHR workflows, CancerIQ makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, cutting-edge clinical solutions, and genomic innovations.